EUCTR2010-022168-11-LV进行中（未招募）1 期
A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-Day Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 658
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Males or females = 18 years old
- •2. ABSSSI meeting at least 1 of the clinical syndrome definitions listed below and requiring systemic oral antibiotic therapy. Local symptoms must have started within 7 days before the Screening Visit.
- •A. Cellulitis/erysipelas defined as a diffuse skin infection, characterized by all of the
- •following within 24 hours:
- •? Rapidly spreading areas of erythema of a minimum surface area of 75 cm2
- •? No collection of pus apparent upon visual examination (diagnosis still consistent with cellulitis/erysipelas if pus is collected from the lesion)
- •? At least 1 of the following signs of infection:
- •? Induration
- •? Localized warmth
- •? Pain or tenderness on palpation
- •? At least 1 of the following systemic signs of infection:
- •? Lymph node tenderness and increase in volume or palpable proximal to the
- •primary ABSSSI
- •? Fever, defined as body temperature = 38°C (100.4°F) oral, = 38.5°C (101.2°F)
- •tympanic, or = 39°C (102.2°F) rectal (observed by a health care provider)
- •? White blood cell (WBC) count = 10,000 cells/mm3 or < 4000 cells/mm3
- •? > 10% immature neutrophils
- •B. Major cutaneous abscess defined as an infection characterized by a collection of pus within the dermis or deeper that is accompanied by all of the following within 24 hours:
- •? Erythema extending at least 5 cm from the peripheral margin of the abscess
- •? At least 1 of the following signs of infection:
- •? Fluctuance
- •? Incision and drainage required
- •? Purulent or seropurulent drainage
- •? Localized warmth
- •? Pain or tenderness on palpation
- •? At least 1 of the following systemic signs of infection:
- •? Lymph node tenderness and increase in volume or palpable proximal to the
- •primary ABSSSI
- •? Fever, defined as body temperature = 38°C (100.4°F) oral, = 38.5°C (101.2°F)
- •tympanic, or = 39°C (102.2°F) rectal (observed by a health care provider)
- •? WBC count = 10,000 cells/mm3 or < 4000 cells/mm3
- •? > 10% immature neutrophils
- •C. Wound Infection defined as an infection of any apparent break in the skin characterized by the following:
- •? Superficial incisional SSI meeting all of the following criteria:
- •? Follows clean surgery (elective, not emergency, nontraumatic, primarily closed,
- •no acute inflammation; no break in technique; respiratory, gastrointestinal,
- •biliary, and genitourinary tracts not entered)
- •? Involves only the skin or subcutaneous tissue around the incision, does not
- •involve fascia
- •? Occurs within 30 days after procedure
- •? Original surgical incision = 3 cm
- •? Purulent drainage from a wound with surrounding erythema extending at least 5
- •cm from the peripheral margin of the wound
- •? At least 1 of the following systemic signs of infection:
- •- Lymph node tenderness and increase in volume or palpable proximal to the
- •primary ABSSS
排除标准
- •1.Uncomplicated skin and skin structure infections (SSSIs) such as furuncles, minor abscesses (area of suppuration not surrounded by cellulitis/erysipelas), impetiginous lesions, superficial or limited cellulitis/erysipelas, and minor wound infections (eg, stitch abscesses)
- •2. Infections associated with, or in close proximity to, a prosthetic device
- •3. Severe sepsis or septic shock
- •4. Known bacteremia at time of screening
- •5. ABSSSI due to or associated with any of the following:
- •? Suspected or documented gram-negative pathogens in patients with
- •cellulitis/erysipelas or major cutaneous abscess that require an antibiotic with specific
- •gram-negative coverage. Patients with wound infections where gram-negative
- •adjunctive therapy is warranted may be enrolled if they meet the other eligibility
- •? Diabetic foot infection, gangrene, or perianal abscess
- •? Concomitant infection at another site not including a secondary ABSSSI lesion (eg,
- •septic arthritis, endocarditis, osteomyelitis)
- •? Infected burns
- •? Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular disease
- •(arterial or venous)
- •? Any evolving necrotizing process (ie, necrotizing fasciitis)
- •? Infected human or animal bites
- •? Infections at vascular catheter sites or involving thrombophlebitis
- •? Incisional SSI with any of the following characteristics:
- •? Follows clean-contaminated surgery (urgent or emergency case that is otherwise
- •clean, elective opening of respiratory, gastrointestinal, biliary, or genitourinary
- •tract with minimal spillage [eg, appendectomy] not encountering infected urine or
- •bile; minor technique break)
- •? Follows contaminated surgery (nonpurulent inflammation; gross spillage from
- •gastrointestinal tract; entry into biliary or genitourinary tract in the presence of
- •infected bile or urine; major break in technique)
- •? Follows dirty surgery (purulent inflammation [eg, abscess]; preoperative
- •perforation of respiratory, gastrointestinal, biliary, or genitourinary tract)
- •? Extends into the fascial or muscle layers, organs, or spaces
- •6. Use of antibiotics as follows:
- •? Systemic antibiotic with gram-positive cocci activity for the treatment of any
- •infection within 96 hours before Dose 1 of study drug
- •? Patients who failed prior therapy for the primary infection site are also excluded
- •from enrollment
- •? Topical antibiotic on the primary lesion except for antibiotic/antiseptic-coated
- •dressing applied to the clean postsurgical wound
- •7. Administration of linezolid within 30 days before Dose 1
- •8. Recent history of opportunistic infections where the underlying cause of these infections is still active (eg, leukemia, transplant, acquired immunodeficiency syndrome [AIDS])
- •9. Receiving chronic systemic immunosuppressive therapy such as prednisone doses = 20 mg per day for = 3 of the last 12 months OR therapies that in the Investigato
研究者
相似试验
进行中（未招募）
1 期
A Phase 3 Randomized, Double-Blind, Multicenter Study Comparingthe Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-DayOral Linezolid for the Treatment of Acute Bacterial Skin and SkinStructure InfectionsAcute Bacterial Skin and Skin Structure InfectionsMedDRA version: 12.1Level: LLTClassification code 10040872Term: Skin infectionEUCTR2010-022168-11-HUTrius Therapeutics, Inc.658
进行中（未招募）
不适用
A Phase 3 Randomized, Double-Blind, Multicenter Study Comparingthe Efficacy and Safety of 6-Day Oral TR-701 Free Acid and 10-DayOral Linezolid for the Treatment of Acute Bacterial Skin and SkinStructure InfectionsAcute Bacterial Skin and Skin Structure InfectionsMedDRA version: 12.1Level: LLTClassification code 10040872Term: Skin infectionEUCTR2010-022168-11-SKTrius Therapeutics, Inc.658
进行中（未招募）
不适用
The purpose of this study is to learn if an experimental antibiotic calledTR-701 FA can safely and effectively treat a acute bacterial skin or skinstructure infection. The experimental antibiotic will be tested against thealready approved antibiotic Linezolid. The sponsor of the study wants toprove, that the new medication isn't inferior regarding efficacy andsafety as compared to the already approved medication Linezolid.EUCTR2010-022168-11-DETrius Therapeutics, Inc.658
进行中（未招募）
不适用
The purpose of this study is to learn if an experimental antibiotic calledTR-701 FA can safely and effectively treat an acute bacterial skin or skinstructure infection. The experimental antibiotic will be tested against thealready approved antibiotic Linezolid adminstered intravenous to oral. The sponsor of the study wants to prove, that the new medication isn't inferior regarding efficacy and safety as compared to the already approved medication Linezolid.EUCTR2011-002860-26-DETrius Therapeutics, Inc.658
进行中（未招募）
不适用
The purpose of this study is to learn if an experimental antibiotic calledTR-701 FA can safely and effectively treat a acute bacterial skin or skinstructure infection. The experimental antibiotic will be tested against thealready approved antibiotic Linezolid. The sponsor of the study wants toprove, that the new medication isn't inferior regarding efficacy andsafety as compared to the already approved medication Linezolid.Acute Bacterial Skin and Skin Structure InfectionsMedDRA version: 13.1Level: PTClassification code 10040872Term: Skin infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2010-022168-11-CZTrius Therapeutics, Inc.658